ライフサイエンスコーパス: autoimmune hepatitis

1 viral causes (alcohol-induced liver disease, autoimmune hepatitis).

2 therapy and represent autoantibody-negative autoimmune hepatitis.

3 osition affect the occurrence and outcome of autoimmune hepatitis.

4 liver regulatory DCs alleviated experimental autoimmune hepatitis.

5 tivated T cells, and alleviate the damage of autoimmune hepatitis.

6 ession but led to spontaneous development of autoimmune hepatitis.

7 e, frequent allograft rejection, and de novo autoimmune hepatitis.

8 , resulting in suppression or stimulation of autoimmune hepatitis.

9 n diagnosis, treatment, and understanding of autoimmune hepatitis.

10 in a model of ConA-mediated T cell-dependent autoimmune hepatitis.

11 rd opportunities to upgrade the treatment of autoimmune hepatitis.

12 ptic liver dysfunction or be associated with autoimmune hepatitis.

13 ccelerated hepatocyte damage in experimental autoimmune hepatitis.

14 sible consequences of corticosteroid-treated autoimmune hepatitis.

15 liver failure and fibrosis in two models of autoimmune hepatitis.

16 hepatitis B, primary biliary cirrhosis, and autoimmune hepatitis.

17 ic patients with posttransplantation de novo autoimmune hepatitis.

18 rine and prednisone similar to treatment for autoimmune hepatitis.

19 Bile duct changes are atypical of autoimmune hepatitis.

20 lure and side effects in treatment-dependent autoimmune hepatitis.

21 ckness-like disease, drug-induced lupus, and autoimmune hepatitis.

22 cyte damage, and thereby serve as a model of autoimmune hepatitis.

23 eviously undescribed histological finding in autoimmune hepatitis.

24 anti-dsDNA are common in ANA-positive type 1 autoimmune hepatitis.

25 is associated with genetic risk factors for autoimmune hepatitis.

26 odies to actin may miss patients with type 1 autoimmune hepatitis.

27 on treatment response and survival in type 1 autoimmune hepatitis.

28 en proposed as diagnostic markers for type 1 autoimmune hepatitis.

29 n of the similarity between the variants and autoimmune hepatitis.

30 ywords: mycophenolate mofetil, Cellcept, and autoimmune hepatitis.

31 ly to do better with even rare diseases like autoimmune hepatitis.

32 ary supplements, antituberculosis drugs, and autoimmune hepatitis.

33 iral hepatitis, it is rarely associated with autoimmune hepatitis.

34 tic approach to target adhesion molecules in autoimmune hepatitis.

35 ctors in regulating cellular immunity during autoimmune hepatitis.

36 hocyte populations in the liver and prevents autoimmune hepatitis.

37 %), acute hepatitis B virus infection (12%), autoimmune hepatitis (12%), and pregnancy-related ALF (2

38 Autoimmune hepatitis (138 cases) was the most frequent p

39 ymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid pa

40 nction, of whom 5 have progressed to de novo autoimmune hepatitis, 2 to chronic rejection, one has pe

41 ation more often than patients with definite autoimmune hepatitis (33% vs. 8%, P = .05).

42 ycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 patients who had experienced tr

43 mune liver disease, 162 patients with type 1 autoimmune hepatitis, 37 patients with primary biliary c

44 apy as commonly as individuals with definite autoimmune hepatitis (75% vs. 64%, P = .5), and they res

45 and development of symptoms consistent with autoimmune hepatitis, a disease previously found to resu

46 angitis, primary sclerosing cholangitis, and autoimmune hepatitis, a family of chronic immune-mediate

47 roup (300 mg daclizumab HYP) died because of autoimmune hepatitis; a contributory role of daclizumab

48 uanine are promising treatments, and de-novo autoimmune hepatitis after liver transplantation suggest

49 ome may lead to diagnostic tests for de-novo autoimmune hepatitis after liver transplantation.

50 Hepatitis C virus can trigger autoimmune hepatitis after needlestick inoculation.

51 HBV) (+71), liver transplantation (+53), and autoimmune hepatitis (AIH) (+27).

52 52), chronic hepatitis C (CHC) (n = 30), and autoimmune hepatitis (AIH) (n = 8).

53 Autoimmune hepatitis (AIH) after liver transplantation (

54 Autoimmune hepatitis (AIH) after liver transplantation h

55 nduction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cho

56 Autoimmune hepatitis (AIH) and autoimmune sclerosing cho

57 Autoimmune hepatitis (AIH) and cryptogenic chronic hepat

58 IF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis

59 is the treatment of choice in patients with autoimmune hepatitis (AIH) and results in remission indu

60 garding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.

61 autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are not well characterized.

62 e cholangitis were distinguished from type 1 autoimmune hepatitis (AIH) by lower serum levels of aspa

63 -induced liver injury (DILI) from idiopathic autoimmune hepatitis (AIH) can be challenging.

64 Autoimmune hepatitis (AIH) can lead to cirrhosis, hepati

65 Autoimmune hepatitis (AIH) disproportionately affects yo

66 A 62-year-old woman with type 1 autoimmune hepatitis (AIH) failed to sustain remission w

67 Immunoglobulin G4 (IgG4) associated autoimmune hepatitis (AIH) has been recognized as a type

68 sus-host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone

69 The understanding of autoimmune hepatitis (AIH) has evolved in the past two d

70 mpact of ethnicity on the natural history of autoimmune hepatitis (AIH) has not been well characteriz

71 The diagnostic criteria for autoimmune hepatitis (AIH) have been codified by an inte

72 Diagnostic criteria for autoimmune hepatitis (AIH) have been created and revised

73 oluble liver antigen (tRNP((Ser)Sec)/SLA) in autoimmune hepatitis (AIH) have been investigated using

74 Patients with autoimmune hepatitis (AIH) have reduced numbers and func

75 ations about liver transplantation (LTX) for autoimmune hepatitis (AIH) have started to emerge, but m

76 Autoimmune hepatitis (AIH) in humans arises spontaneousl

77 Autoimmune hepatitis (AIH) in pregnancy has many unique

78 Caucasian female, with a prior diagnosis of autoimmune hepatitis (AIH) in remission, presented with

79 re described, who went on to develop de novo autoimmune hepatitis (AIH) in the transplanted liver.

80 Data on the epidemiology of autoimmune hepatitis (AIH) in the United States are limi

81 Autoimmune hepatitis (AIH) is a chronic inflammatory con

82 Autoimmune hepatitis (AIH) is a chronic inflammatory dis

83 Autoimmune hepatitis (AIH) is a chronic inflammatory liv

84 Autoimmune hepatitis (AIH) is a chronic inflammatory liv

85 Autoimmune hepatitis (AIH) is a chronic liver disease th

86 Autoimmune hepatitis (AIH) is a chronic progressive infl

87 Autoimmune hepatitis (AIH) is a chronic, progressive hep

88 Autoimmune hepatitis (AIH) is a rare autoimmune disease

89 Autoimmune hepatitis (AIH) is a rare disease of unclear

90 Autoimmune hepatitis (AIH) is a typical T cell-mediated

91 Autoimmune hepatitis (AIH) is an important cause of seve

92 Autoimmune hepatitis (AIH) is an uncommon autoimmune liv

93 Susceptibility to autoimmune hepatitis (AIH) is associated with the HLA A1

94 Autoimmune hepatitis (AIH) is characterized by a loss of

95 Autoimmune hepatitis (AIH) is characterized by chronic i

96 Autoimmune hepatitis (AIH) is defined as a chronic liver

97 en reported in early childhood, while type 2 autoimmune hepatitis (AIH) is eminently a paediatric dis

98 Genetic involvement in type 1 autoimmune hepatitis (AIH) is indicated by a marked fema

99 Autoimmune hepatitis (AIH) is known as a T cell-mediated

100 The etiopathogenesis of autoimmune hepatitis (AIH) remains poorly understood.

101 Autoimmune hepatitis (AIH) typically responds to treatme

102 Classical serological biomarkers of autoimmune hepatitis (AIH) were only sporadically positi

103 epresent an immune intervention candidate in autoimmune hepatitis (AIH), a condition characterized by

104 of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have

105 BACKGROUND/AIM: It remains uncertain whether autoimmune hepatitis (AIH), as an original indication fo

106 prine (AZA) is used to maintain remission in autoimmune hepatitis (AIH), but up to 18% of patients ar

107 enesis of autoimmune liver diseases, such as autoimmune hepatitis (AIH), has been hampered by a lack

108 epatitis, the histological lesion typical of autoimmune hepatitis (AIH), is composed of CD4 and CD8 T

109 In autoimmune hepatitis (AIH), liver-damaging CD4 T cell re

110 ata on the mortality and cancer incidence of autoimmune hepatitis (AIH), primary biliary cirrhosis (P

111 rare complication of cirrhosis secondary to autoimmune hepatitis (AIH), yet the true incidence remai

112 re defective numerically and functionally in autoimmune hepatitis (AIH).

113 ulfilled the diagnostic criteria for de novo autoimmune hepatitis (AIH).

114 oms of certain autoimmune diseases including autoimmune hepatitis (AIH).

115 ), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH).

116 used as standard or alternative therapies in autoimmune hepatitis (AIH).

117 f autoantibodies is a mainstay of diagnosing autoimmune hepatitis (AIH).

118 tiple organs, and 20% of patients develop an autoimmune hepatitis (AIH).

119 l and immunological characteristics of human autoimmune hepatitis (AIH).

120 olangitis, hepatitis B or C virus infection, autoimmune hepatitis, alcoholic liver disease, or withou

121 les associated with susceptibility to type 1 autoimmune hepatitis also influence its clinical feature

122 ocytes in various liver pathologies, such as autoimmune hepatitis and alcoholic hepatitis.

123 to treat inflammatory liver diseases such as autoimmune hepatitis and alcoholic hepatitis.

124 ch patients have findings indicative of both autoimmune hepatitis and another disorder (overlap syndr

125 IH, we identified susceptibility factors for autoimmune hepatitis and attempted to restore immunologi

126 ) proteins in Tregs of patients with de novo autoimmune hepatitis and autoimmune hepatitis, which ind

127 in autoimmune liver disease (AILD; including autoimmune hepatitis and autoimmune sclerosing cholangit

128 ace, and it can be targeted by antibodies in autoimmune hepatitis and chronic hepatitis C.

129 that improve the diagnosis and treatment of autoimmune hepatitis and extend the understanding of its

130 that improve the diagnosis and treatment of autoimmune hepatitis and extend understanding of its pat

131 It is also linked to two human diseases, autoimmune hepatitis and glutamate formiminotransferase

132 tosis, is upregulated and activated in human autoimmune hepatitis and in a murine model of inflammati

133 diseases primary sclerosing cholangitis and autoimmune hepatitis and inflammatory bowel disease, we

134 Azathioprine is commonly prescribed for autoimmune hepatitis and inflammatory bowel disease.

135 chronic hepatitis is indistinguishable from autoimmune hepatitis and it responds as well to corticos

136 the bases for the classification of probable autoimmune hepatitis and its clinical importance.

137 llele is more common in patients with type 1 autoimmune hepatitis and may represent a second suscepti

138 ognized by autoantibodies from patients with autoimmune hepatitis and on the binding of thin vimentin

139 that improve the diagnosis and treatment of autoimmune hepatitis and presage new drug and molecular

140 Variant forms, including syndromes with autoimmune hepatitis and primary biliary cirrhosis (7%)

141 Individuals with autoimmune hepatitis and primary biliary cirrhosis enter

142 Overlap syndromes include combinations of autoimmune hepatitis and primary biliary cirrhosis, prim

143 an be effective in patients with features of autoimmune hepatitis and primary biliary cirrhosis.

144 Patients with autoimmune hepatitis and primary sclerosing cholangitis

145 and they responded better than patients with autoimmune hepatitis and primary sclerosing cholangitis

146 that improve the diagnosis and treatment of autoimmune hepatitis and suggest new drug and molecular

147 We report a case of autoimmune hepatitis and the subsequent, rarely occurrin

148 esonide in patients with treatment-dependent autoimmune hepatitis and to determine if efficacy and sa

149 cientist can contribute to the maturation of autoimmune hepatitis and to illustrate the principles of

150 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, and 40 with systemic lupus erythem

151 with PSC had higher odds of developing IBD, autoimmune hepatitis, and any autoimmune disease than re

152 ts of Fas ligand are abnormally increased in autoimmune hepatitis, and apoptotic dysfunction may cont

153 Pregnancy is not contraindicated in autoimmune hepatitis, and cyclosporine may be effective

154 ease such as steatohepatitis, iron overload, autoimmune hepatitis, and drug-induced injury.

155 tamol toxicity, hepatic ischaemia, viral and autoimmune hepatitis, and drug-induced liver injury from

156 advances promise to improve the treatment of autoimmune hepatitis, and investigations of these advanc

157 inical and laboratory features that resemble autoimmune hepatitis, and it may respond initially to co

158 Hepatitis B virus, hepatitis C virus, autoimmune hepatitis, and nonalcoholic fatty liver disea

159 up contained mainly alcoholic liver disease, autoimmune hepatitis, and primary biliary cirrhosis.

160 ver diseases, including alcoholic hepatitis, autoimmune hepatitis, and primary biliary cirrhosis.

161 satisfied international scoring criteria for autoimmune hepatitis, and the findings were correlated w

162 ed that biliary changes can occur in classic autoimmune hepatitis, and they are not associated with d

163 ibodies lack sensitivity and specificity for autoimmune hepatitis, and they have diverse antigen spec

164 ecrosis is within the histologic spectrum of autoimmune hepatitis, and variant syndromes may be refra

165 ochromatosis, alpha1-antitrypsin deficiency, autoimmune hepatitis, and Wilson's disease.

166 vation-induced cell death may be impaired in autoimmune hepatitis, and, in contrast to budesonide, my

167 Variant forms of autoimmune hepatitis are common.

168 The incidence and prevalence of autoimmune hepatitis are greater than expected among whi

169 Outcomes of autoimmune hepatitis are poor in our setting but access

170 Identifying autoimmune hepatitis as the etiology of acute liver fail

171 ry liver disease states, including viral and autoimmune hepatitis as well as liver allograft rejectio

172 s, 44 patients transplanted for cryptogenic, autoimmune, hepatitis B, or cholestatic liver disease an

173 tinguished from those designated as definite autoimmune hepatitis by male sex, concurrent immune dise

174 Twenty-seven patients designated as probable autoimmune hepatitis by one system were designated as de

175 The designation of probable autoimmune hepatitis by the international scoring system

176 is by one system were designated as definite autoimmune hepatitis by the other system.

177 enteen patients (9%) were graded as probable autoimmune hepatitis by the revised original scoring sys

178 rimary sclerosing cholangitis (PSC), chronic autoimmune hepatitis (CAH), systemic lupus erythematosus

179 Autoimmune hepatitis can affect diverse ethnic groups, a

180 De-novo autoimmune hepatitis can occur in adults and children af

181 Autoimmune hepatitis can present as acute or chronic hep

182 Autoimmune hepatitis can present as an acute or fulminan

183 The diagnostic scoring systems for autoimmune hepatitis categorize some patients as having

184 Autoimmune hepatitis causes chronic hepatitis and often

185 , alcoholic cirrhosis (AC) (n = 16 810), and autoimmune hepatitis cirrhosis (AIH) (n = 2734).

186 (n = 189), alcoholic cirrhosis (n = 300) or autoimmune hepatitis cirrhosis (n = 118) after excluding

187 he criteria established by the International Autoimmune Hepatitis Club.

188 Clinical phenotypes of autoimmune hepatitis commonly include rheumatic manifest

189 Autoimmune hepatitis commonly relapses after corticoster

190 De novo autoimmune hepatitis, consisting of histological chronic

191 s (hepatitis B virus, hepatitis C virus, and autoimmune hepatitis) contain increased numbers of PD-1-

192 henotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular r

193 we show that Tregs of patients with de novo autoimmune hepatitis (dAIH) display increased frequencie

194 of treatment failure in patients with type 1 autoimmune hepatitis, define features associated with it

195 n of the clinically useful short form of the autoimmune hepatitis diagnostic scoring system; accumula

196 orticosteroids improve survival in fulminant autoimmune hepatitis, drug-induced, or indeterminate ALF

197 that clarify the rheumatic manifestations of autoimmune hepatitis, elucidate shared pathogenic pathwa

198 Autoimmune hepatitis emerged during an era when concepts

199 Autoimmune hepatitis exemplifies an evolutionary process

200 Subjects with obesity, type 2 diabetes, and autoimmune hepatitis exhibited lower levels of unmethyla

201 Autoimmune hepatitis (five [4%] patients), primary bilia

202 efinite AIH" under the revised International Autoimmune Hepatitis Group (IAIHG) scoring system.

203 een created and revised by the International Autoimmune Hepatitis Group (IAIHG).

204 A clinical subcommittee of the International Autoimmune Hepatitis Group reviewed current management d

205 International Autoimmune Hepatitis Group scores were calculated.

206 On the International Autoimmune Hepatitis Group scoring system, five patients

207 ease, and the formation of the International Autoimmune Hepatitis Group standardized the diagnosis, i

208 Autoimmune hepatitis has a global distribution and diver

209 Autoimmune hepatitis has a global distribution, and its

210 Susceptibility for type 1 autoimmune hepatitis has been associated with the major

211 Autoimmune hepatitis has clinical manifestations, serolo

212 Autoimmune hepatitis has diverse presentations and manif

213 Patients with type 2 autoimmune hepatitis have different HLA frequencies than

214 y cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hepatitis B virus, and hepatitis C

215 In contrast to classical autoimmune hepatitis, histological features of AI-ALF pr

216 s (ANA) failed to establish the diagnosis of autoimmune hepatitis in 5 patients.

217 in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrho

218 DRB1*1301 is associated with autoimmune hepatitis in Brazil, especially among childre

219 Autoimmune hepatitis in children may be associated with

220 mary sclerosing cholangitis may overlap with autoimmune hepatitis in some cases, although the real pr

221 sclerosing cholangitis in children can mimic autoimmune hepatitis in the absence of inflammatory bowe

222 eactivity, although such knowledge in type 2 autoimmune hepatitis, in which the known autoantigen is

223 lucocorticoids in the long-term treatment of autoimmune hepatitis, including azathioprine, a purine a

224 Smad3 signaling in an experimental model of autoimmune hepatitis induced by concanavalin A (ConA), a

225 hyma but not in lymphoid cells protects from autoimmune hepatitis induced by mitogen concanavalin A (

226 Autoimmune hepatitis initially had to be distinguished f

227 Autoimmune hepatitis is a disease of the hepatic parench

228 Autoimmune hepatitis is as virulent in the elderly as in

229 omposite histological pattern that resembles autoimmune hepatitis is associated with greater immunore

230 In common with many autoimmune diseases, autoimmune hepatitis is associated with non-organ-specif

231 Autoimmune hepatitis is classically a disease of young w

232 that liver damage in this model of fulminant autoimmune hepatitis is driven by CD4(+) T cell producti

233 Although the treatment of choice for autoimmune hepatitis is glucocorticoids, their side effe

234 Genetic susceptibility to type 1 autoimmune hepatitis is indicated by a preponderance of

235 The classical histological finding in autoimmune hepatitis is lymphocytic infiltration of the

236 nts with chronic hepatitis, the diagnosis of autoimmune hepatitis is made on the basis of increased g

237 A few case reports of autoimmune hepatitis-like liver injury have been reporte

238 tures that mimic other diseases, such as the autoimmune hepatitis-like syndrome that may follow liver

239 re not abnormal universally in patients with autoimmune hepatitis, liver biopsy remains an important

240 Autoimmune hepatitis may fail to respond to corticostero

241 Children with autoimmune hepatitis may have abnormal cholangiogram res

242 Recurrent or de novo autoimmune hepatitis must be considered as a cause of gr

243 Autoimmune hepatitis must be considered in all patients

244 ients with chronic viral hepatitis (n = 22), autoimmune hepatitis (n = 10), and obstructive jaundice

245 s C (n=16), cryptogenic cirrhosis (n=2), and autoimmune hepatitis (n=1).

246 s (n= 19), sclerosing cholangitis (n=6), and autoimmune hepatitis (n=5) (group II).

247 -11.7; male/female, 23/33], 22 with ALF-CLD (autoimmune hepatitis, n = 14; Wilson disease, n = 6; inb

248 ulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy,

249 Autoimmune hepatitis occurred in patients aged 18-30 yea

250 Autoimmune disease (ie, autoimmune hepatitis) occurred in a single individual (2

251 None of the 15 controls developed de novo autoimmune hepatitis or any other form of persistent gra

252 nsplanted at experienced centers with either autoimmune hepatitis or cholestatic liver disease had si

253 a concomitant inflammatory bowel disease, an autoimmune hepatitis or immunosuppressive medication was

254 on, nonsteroidal anti-inflammatory drugs, or autoimmune hepatitis) or patients without acute liver fa

255 ronic infection with hepatitis B or C virus, autoimmune hepatitis, or alcoholic liver disease, we det

256 Retransplant recipients, patients with autoimmune hepatitis, or status 1 or 2A patients were ex

257 and pathologically distinct from idiopathic autoimmune hepatitis, our understanding of its pathogene

258 inconsistent with the classic definition of autoimmune hepatitis (outlier syndromes).

259 e diseases, and/or subsequent development of autoimmune hepatitis overlap syndrome.

260 Presence of autoimmune hepatitis overlapping with PSC (P =.2) or med

261 Autoimmune hepatitis overlapping with PSC was present in

262 DR-locus mismatch increased recurrence of autoimmune hepatitis (P = 0.01, HR = 4.2) and primary bi

263 lysis were more likely to have the classical autoimmune hepatitis phenotype (female predominance [72%

264 t polycystic livers and might also influence autoimmune hepatitis, primary biliary cirrhosis, and cho

265 xist with autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and pri

266 Patients with autoimmune hepatitis, primary sclerosing cholangitis, an

267 A few patients developed alopecia, autoimmune hepatitis, psoriasis, and psoriatic arthritis

268 e has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver inj

269 e reviews the relevant literature of de novo autoimmune hepatitis, recurrent autoimmune hepatitis, re

270 e of de novo autoimmune hepatitis, recurrent autoimmune hepatitis, recurrent primary sclerosing chola

271 wo (<1%) patients in the atezolizumab group (autoimmune hepatitis related to atezolizumab [n=1] and s

272 atitis (score of 10-15) and one had definite autoimmune hepatitis (score > 15) at the onset of graft

273 p scoring system, five patients had probable autoimmune hepatitis (score of 10-15) and one had defini

274 n antinuclear antibody (ANA)-positive type 1 autoimmune hepatitis, sera from 53 patients were tested

275 l, smoking, diabetes, hepatitis D and E, and autoimmune hepatitis serological markers.

276 Autoimmune hepatitis should be considered in all patient

277 , the ulcers completely healed, and with the autoimmune hepatitis still in remission.

278 Progress in type 1 autoimmune hepatitis still requires knowledge of a disea

279 taining in liver biopsies from patients with autoimmune hepatitis suggests a role for MLKL in this di

280 hemochromatosis gene occurs more commonly in autoimmune hepatitis than in normal subjects, but it is

281 occurs more commonly in patients with type 1 autoimmune hepatitis than in normal subjects; it is asso

282 with systemic lupus erythematosus (SLE) and autoimmune hepatitis, two extraintestinal autoimmune dis

283 Autoimmune hepatitis type 2 (AIH-2) is a severe organ-sp

284 chrome P450IID6 (CYP2D6), the autoantigen of autoimmune hepatitis type 2 (AIH-2), are permitted by a

285 chrome P450IID6 (CYP2D6), the autoantigen of autoimmune hepatitis type 2 (AIH-2), are permitted by a

286 time, the significance of Smad3 signaling in autoimmune hepatitis, underlining the control of Smad3-d

287 et al. demonstrate that, in a mouse model of autoimmune hepatitis, viral infections not only trigger

288 Autoimmune hepatitis was associated with an increased ri

289 Hepatitis or autoimmune hepatitis was the only serious adverse event

290 Female sex and autoimmune hepatitis were associated with an increased r

291 onsequences of these polymorphisms in type 1 autoimmune hepatitis were determined.

292 e North American adults with definite type 1 autoimmune hepatitis were grouped according to age at pr

293 Diagnostic scores for autoimmune hepatitis were lower in patients with bile du

294 Sera from 99 patients with type 1 autoimmune hepatitis were tested.

295 ry tests in problematic patients with type 1 autoimmune hepatitis when administered adjunctively for

296 Our data show that symptoms of autoimmune hepatitis, which are responsive to the classi

297 tients with de novo autoimmune hepatitis and autoimmune hepatitis, which induces endoplasmic reticulu

298 We report a patient with autoimmune hepatitis who developed severe small-bowel vi

299 We report 3 patients with autoimmune hepatitis who either could not tolerate or fa

300 were classified as ALF-CLD if diagnosed with autoimmune hepatitis, Wilson disease, Budd-Chiari syndro